The latest news from academia, regulators
research labs and other things of interest
Posted: September 21, 2007
Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices
(Nanowerk News) Research and Markets has announced the addition of Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices to their offering.
Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. ‘Innovations in Cardiovascular Disease Management’ is a new report that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities.
Some key findings from this report:
-The worldwide market for coronary stents was valued at $6.18bn in 2006, and with a projected CAGR of 11.6%, is expected to be valued at $13.34bn by the year 2013. Estimates show that 95.9% of all PCI procedures in 2006 included a BMS or DES coronary stent.
-The coronary stent market is likely to be revolutionised by novel advancements including Absorbable Metal Stent (AMS) Technologies, novel coating technologies, gene therapy technologies, Endothelial Progenitor Cells, nanotechnologies, drug-eluting coronary stents, novel Estradiol containing drug-eluting stents and regenerative stents.
-Novartis’ Rasilez (aliskiren) and Exforge (valsartan/amlodipine) are two major anti-hyperintensives set be launched in 2007. Novartis’ Tektuma was US FDA approved in early 2007, with EMEA approval for the treatment of high blood pressure also expected later this year.
-In April 2007, Abbot Laboratories submitted an NDA to the FDA for a fixed dose combination Niaspan (extended release niacin) and Simvastin, whilst hoping to launch Simcor at the start of 2008.
-A total of 126 New Chemical Entities (NCE’s) are currently in preclinical trials, including 51 in Phase I and 122 in Phase II.
For more information visit http://www.researchandmarkets.com/reports/c69221